FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 406 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Alectinib Approved as an Adjuvant Treatment for Lung Cancer May 8, 2024 Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... March 29, 2019 Health inequalities: breaking down barriers to cancer screening September 23, 2022 A celebration of peer review September 21, 2021 Load more HOT NEWS Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Resource Round-Up: Let’s Win Pancreatic Cancer What to Know About Returning to Work After Cancer Treatment: An... Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly...
